KNSA's PB Ratio is ranked worse than 90.02% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.855
vs KNSA: 7.34
During the past 12 months, Kiniksa Pharmaceuticals International's average Book Value Per Share Growth Rate was 25.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 9.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 15.30% per year.
During the past 10 years, the highest 3-Year average Book Value Per Share Growth Rate of Kiniksa Pharmaceuticals International was 31.20% per year. The lowest was -22.00% per year. And the median was 10.80% per year.
Back to Basics: PB Ratio
Kiniksa Pharmaceuticals International (NAS:KNSA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Kiniksa Pharmaceuticals International PB Ratio Related Terms
Kiniksa Pharmaceuticals International PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kiniksa Pharmaceuticals International PB Ratio Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kiniksa Pharmaceuticals International PB Ratio vs Drug Manufacturers Industry
Kiniksa Pharmaceuticals International PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Kiniksa Pharmaceuticals International (KNSA) has a PB Ratio of 7.34 as of Jun. 25, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kiniksa Pharmaceuticals International and its competitors. This is 104% above median its historical median of 3.60. Over the past decade, Kiniksa Pharmaceuticals International's PB Ratio has ranged from 1.92 to 7.56. According to the industry distribution chart, Kiniksa Pharmaceuticals International ranks #830 out of 922 companies in the Drug Manufacturers industry, placing it in the top 90%.
Is Kiniksa Pharmaceuticals International's PB Ratio too high?
Kiniksa Pharmaceuticals International's current PB Ratio of 7.34 is 104% above median its 10-year median of 3.60. Over the past 10 years, this metric has ranged from a low of 1.92 to a high of 7.56. The Drug Manufacturers industry median PB Ratio is 1.86. Kiniksa Pharmaceuticals International's value of 7.34 is 295.7% above this industry median. Based on the distribution chart, Kiniksa Pharmaceuticals International ranks #830 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Kiniksa Pharmaceuticals International has a GF Score™ of 56/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kiniksa Pharmaceuticals International's PB Ratio compare to AMRX and INDV?
According to the Drug Manufacturers industry distribution chart, Kiniksa Pharmaceuticals International ranks #830 out of 922 companies for PB Ratio. This places Kiniksa Pharmaceuticals International in the lower half of its industry. The industry median PB Ratio is 1.86. Kiniksa Pharmaceuticals International's value of 7.34 is 295.7% above this benchmark. Historically, Kiniksa Pharmaceuticals International's own PB Ratio has ranged from 1.92 to 7.56 over the past decade. While the company's 10-year median is 3.60 vs. the industry median of 1.86, Kiniksa Pharmaceuticals International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.86, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kiniksa Pharmaceuticals International's current PB Ratio of 7.34 is 295.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Kiniksa Pharmaceuticals International and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kiniksa Pharmaceuticals International's current PB Ratio is 7.34, which is 104% above median its own 10-year median of 3.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kiniksa Pharmaceuticals International stock overvalued right now?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International (KNSA) is currently considered Modestly Overvalued. The stock's GF Value™ is $47.89, compared to a current price of $58.00 — trading 21.1% above its estimated fair value. The current PB Ratio is 7.34, which is 104% above median its 10-year median of 3.60 and 295.7% above the Drug Manufacturers industry median of 1.86. Kiniksa Pharmaceuticals International's overall GF Score™ is 56/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Kiniksa Pharmaceuticals International (KNSA), the current PB Ratio is 7.34 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Kiniksa Pharmaceuticals International (KNSA) Overvalued in 2026?
Based on GuruFocus' analysis, Kiniksa Pharmaceuticals International stock appears to be overvalued.
The current stock price of $58.00 is trading 21.1% above its estimated GF Value™ of $47.89.
GuruFocus considers Kiniksa Pharmaceuticals International to be Modestly Overvalued.
Key valuation signals for KNSA:
PB Ratio: 7.34 (104% above median its 10-year median of 3.60)
GF Value™: $47.89 vs. price of $58.00 (21.1% above fair value)
Industry Position: 295.7% above the Drug Manufacturers median (#830 of 922)
No single metric tells the full story. See the KNSA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Kiniksa Pharmaceuticals International Business Description
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
56GF Score
Get the complete analysis for KNSA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KNSA has been successfully added to your 
